Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2208 results found since Jan 2013.
Design, development, and in-vitro/in-vivo evaluation of Docetaxel-loaded PEGylated Solid Lipid Nanoparticles in Prostate Cancer Therapy
Eur J Pharm Biopharm. 2023 Jun 1:S0939-6411(23)00142-X. doi: 10.1016/j.ejpb.2023.05.020. Online ahead of print.ABSTRACTDocetaxel (DOC) is a potent anticancer molecule widely used to treat various cancers. However, its therapeutic efficacy as a potential anticancer agent has been limited owing to poor aqueous solubility, short circulation time, rapid reticuloendothelial system uptake, and high renal clearance, which consecutively showed poor bioavailability. In the present investigation, we developed polyethylene glycol (PEG) decorated solid lipid nanoparticles (SLN) using the solvent diffusion method to increase the biopha...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 3, 2023 Category: Drugs & Pharmacology Authors: Swati Korake C Bothiraja Atmaram Pawar Source Type: research
Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
J Clin Oncol. 2023 Jun 2:JCO2300723. doi: 10.1200/JCO.23.00723. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.For generation...
Source: Clinical Prostate Cancer - June 2, 2023 Category: Cancer & Oncology Authors: Jeremiah Wala Paul Nguyen Mark Pomerantz Source Type: research
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
CONCLUSIONS: Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.PMID:37263910 | DOI:10.1016/j.clgc.2023.05.003
Source: Clinical Prostate Cancer - June 1, 2023 Category: Cancer & Oncology Authors: Valentina Orlando Damien Drubay Pernelle Lavaud Laura Faivre Fran çois Lesaunier Remy Delva Gwena ëlle Gravis Fr édéric Rolland Frank Priou Jean-Marc Ferrero Nadine Houede Loic Mourey Christine Theodore Ivan Krakowski Jean-Fran çois Berdah Marjorie B Source Type: research
Is Hypoglycemia Secondary to Metastatic Retroperitoneal Sarcoma -A Therapeutic Challenge? Case Report and Review of Literature
Curr Probl Cancer. 2023 May 14;47(3):100961. doi: 10.1016/j.currproblcancer.2023.100961. Online ahead of print.ABSTRACTMost soft tissue sarcomas afflict the extremities; however, the retro peritoneum can also be affected rarely. Retroperitoneal sarcomas are relatively asymptomatic. Although tumor-induced hypoglycemia is rare in tumors other than insulinomas, extrapancreatic tumors are a subset that displays this phenomenon. The occurrence of hypo-insulinemic hypoglycemia with low GH and IGF-1 should prompt consideration of the secretion of a hypoglycemic substance impeding the secretion of insulin and GH, such as IGF-2 or ...
Source: Cancer Control - June 1, 2023 Category: Cancer & Oncology Authors: Rishi P Nair Atul Kumar Gupta Puneet Pareek Bharti Devnani Sandeep Kumar Bairwa Pawan K Garg Divya Aggarwal Smily Sharma Tushar Mittal Source Type: research
Identification of potential benzoxazolinone as CYP1B1 inhibitors via molecular docking, dynamics, waterswap, and In vitro analysis
New J. Chem., 2023, Accepted Manuscript DOI: 10.1039/D3NJ01138K, PaperBaddipadige Raju, Himanshu Verma, Gera Narendra, Gurleen Kaur Tung, Subheet Kumar Jain, Om Silakari Overexpression of Cytochrome P450 1B1 in malignancies is accountable for the biotransformation-based inactivation of various chemotherapeutics such as docetaxel, paclitaxel, cisplatin, and tamoxifen. Additionally, it also plays a major role... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - May 31, 2023 Category: Chemistry Authors: Baddipadige Raju Source Type: research
The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells
CONCLUSION: The CCL2-CCR2 axis is a key contributor to resistance to the antimigration effect of cabazitaxel in prostate cancer cells. CCL2-CCR2 axis inhibition may be a potential therapeutic target against chemoresistant CRPC in combination with cabazitaxel.PMID:37247914 | DOI:10.21873/anticanres.16423
Source: Cell Research - May 29, 2023 Category: Cytology Authors: Ariunbold Natsagdorj Kouji Izumi Kaoru Hiratsuka Renato Naito Suguru Kadomoto Hiroaki Iwamoto Hiroshi Yaegashi Kazuyoshi Shigehara Hiroki Nakata Atsushi Mizokami Source Type: research
Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data
This study aimed to generate real-world evidence on treatment patterns, clinical outcomes, health care resource utilization (HCRU), and costs among older patients with metastatic castration-resistant PC (mCRPC).MATERIALS AND METHODS: A claims algorithm based on treatments expected for mCRPC was used to identify men ≥65 years old with mCRPC in the SEER-Medicare data between 2007 and 2019. The index date was defined as the date of the start of first-line therapy (1L). Treatment patterns and all-cause and PC-specific HCRU and costs were measured in the 12 months preindex period and the postindex follow-up period. Time to ne...
Source: Clinical Prostate Cancer - May 29, 2023 Category: Cancer & Oncology Authors: Umang Swami Himani Aggarwal Mo Zhou Shan Jiang Jeri Kim Weiyan Li Fran çois Laliberté Bruno Emond Neeraj Agarwal Source Type: research
Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
This study demonstrates the in vivo radioenhancement potential of chemotherapy combined with therapeutic ultrasound-microbubble treatment in inducing cell death and apoptosis, as well as long-term tumor shrinkage.PMID:37242710 | DOI:10.3390/pharmaceutics15051468
Source: Cancer Control - May 27, 2023 Category: Cancer & Oncology Authors: Firas Almasri Emmanuel H Sakarya Raffi Karshafian Source Type: research
